ANI Pharmaceuticals, Inc. $ANIP Shares Sold by Aberdeen Group plc

Aberdeen Group plc lowered its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 10.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 240,792 shares of the specialty pharmaceutical company’s stock after selling 28,886 shares during the period. Aberdeen Group plc owned about 1.07% of ANI Pharmaceuticals worth $19,008,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Hantz Financial Services Inc. grew its stake in shares of ANI Pharmaceuticals by 202.6% in the 3rd quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock worth $32,000 after purchasing an additional 237 shares during the last quarter. Advisors Asset Management Inc. purchased a new position in shares of ANI Pharmaceuticals in the first quarter worth approximately $28,000. Newbridge Financial Services Group Inc. increased its position in shares of ANI Pharmaceuticals by 200.0% in the second quarter. Newbridge Financial Services Group Inc. now owns 600 shares of the specialty pharmaceutical company’s stock worth $39,000 after acquiring an additional 400 shares in the last quarter. State of Wyoming purchased a new position in shares of ANI Pharmaceuticals in the second quarter worth approximately $50,000. Finally, CWM LLC increased its position in shares of ANI Pharmaceuticals by 159.1% in the third quarter. CWM LLC now owns 798 shares of the specialty pharmaceutical company’s stock worth $73,000 after acquiring an additional 490 shares in the last quarter. Institutional investors and hedge funds own 76.05% of the company’s stock.

Insiders Place Their Bets

In related news, insider Christopher Mutz sold 3,162 shares of the business’s stock in a transaction on Friday, March 13th. The shares were sold at an average price of $71.64, for a total transaction of $226,525.68. Following the transaction, the insider owned 91,309 shares of the company’s stock, valued at approximately $6,541,376.76. The trade was a 3.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Thomas Andrew Rowland sold 4,772 shares of the business’s stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $74.91, for a total transaction of $357,470.52. Following the transaction, the senior vice president directly owned 38,730 shares in the company, valued at $2,901,264.30. This trade represents a 10.97% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 27,860 shares of company stock valued at $2,114,771 in the last three months. Company insiders own 11.10% of the company’s stock.

Wall Street Analyst Weigh In

ANIP has been the subject of several research reports. Guggenheim raised their price target on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a “buy” rating in a report on Friday, January 16th. Wall Street Zen cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, March 14th. Barclays initiated coverage on shares of ANI Pharmaceuticals in a report on Tuesday, December 9th. They set an “overweight” rating and a $100.00 price target for the company. Zacks Research cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 6th. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research note on Monday, December 29th. Five analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $107.33.

ANI Pharmaceuticals Price Performance

Shares of ANI Pharmaceuticals stock opened at $77.20 on Tuesday. The firm has a fifty day simple moving average of $76.52 and a 200-day simple moving average of $82.82. The company has a current ratio of 2.71, a quick ratio of 2.19 and a debt-to-equity ratio of 1.11. ANI Pharmaceuticals, Inc. has a 1-year low of $56.71 and a 1-year high of $99.50. The stock has a market capitalization of $1.73 billion, a price-to-earnings ratio of 22.98 and a beta of 0.44.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.